LOGIN  |  REGISTER
Recursion
Assertio

For the Second Year in a Row, Veeva Systems MedTech Named Best Overall Medtech Software

May 22, 2024 | Last Trade: US$212.04 1.97 -0.92
  • Annual MedTech Breakthrough Awards program recognizes leading companies in medical devices and diagnostics

PLEASANTON, Calif., May 22, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva MedTech was named "Best Overall MedTech Software" for the second year in a row in the 8th annual MedTech Breakthrough Awards program. The awards honor excellence and recognize innovation, commitment, and success across a range of health and medical technology categories.

"Veeva MedTech pairs deep industry expertise and advanced technology to help medtech companies streamline processes with greater control," said Steve Johansson, managing director, MedTech Breakthrough. "With Veeva MedTech, device and diagnostic companies can manage mission-critical processes using unified and connected applications on a single cloud platform. Congratulations to Veeva for winning best overall medtech software."

More than 125 companies are partnering with Veeva MedTech to keep up with evolving regulations and market requirements. By adopting advanced applications with built-in industry best practices, medtechs can streamline operations for greater efficiency, speed, and compliance.

"With more than 15 years of experience in the life sciences and medtech industries, Veeva works closely with customers to address complex challenges that can move the industry forward," said Seth Goldenberg, vice president at Veeva MedTech. "We're thrilled to achieve this recognition and will continue to deliver innovations that help our customers get products to patients faster."

Veeva MedTech enables end-to-end product lifecycle management with Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Quality, Veeva Vault Commercial, and Veeva Medical. Overall, this is Veeva MedTech's third MedTech Breakthrough Award recognition, winning "Best Clinical Efficiency Solution" in 2022. To learn more about Veeva MedTech, please visit veeva.com/medtech.

About MedTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services, and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include patient experience and engagement, health and fitness, medical devices, clinical administration, connected healthcare, medical data, healthcare cybersecurity, and more. For more information, visit MedTechBreakthrough.com

Tech Breakthrough LLC does not endorse any vendor, product, or service depicted in our recognition programs and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Deivis Mercado
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Astria Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB